NEW YORK (360Dx) – Thermo Fisher Scientific disclosed in a recent regulatory filing that the aggregate purchase price for IntegenX was $65 million. In March, the company announced that it had acquired IntegenX, a developer of rapid DNA testing technology for forensics and human identification.
Agilent Technologies said this week that it has completed its previously announced acquisition of Lasergen. Agilent made its initial investment in the privately held company in March 2016, acquiring a 48 percent ownership stake with a two-year call option to acquire the remaining shares for $105 million. Agilent gave its notice to exercise the option on February 23. Since the initial investment, Lasergen and Agilent have been collaborating to develop a workflow solution for clinical applications based on next-generation sequencing, using Lasergen's Lightning Terminators chemistry.
HalioDx said this week that its Immunoscore Colon CE-IVD workflow is compatible with the Philips IntelliSite Pathology Solution, a high-throughput digital pathology solution for primary diagnosis. The collaboration aims to provide a clinically validated and regulatory compliant workflow using both companies’ technologies, HalioDx said. The US Food and Drug Administration cleared Philips’ technology for primary diagnosis last year. Immunoscore Colon, meanwhile, predicts a patient’s risk of recurrence with localized colon cancer to guide treatment decisions.
Instrumentation Laboratory said this week that its total worldwide sales grew 22 percent year over year in 2017 to $970 million. Organic growth was almost 7 percent, while corporate acquisitions grew sales by almost 16 percent. Among Instrumentation Laboratory’s buys in 2017 was its purchase of Accriva Diagnostics.
Omega Diagnostics said this week that it has CE-marked two more allergens, extending the menu to 53 allergens that can be run on Immunodiagnostic Systems’ fully automated IDS instrument. The allergens will be available to Immunodiagnostic Systems under a global distribution deal forged last month.
Invivoscribe Technologies said this week that it is collaborating with the American University of Beirut Medical Center in Lebanon to create a reference laboratory that offers specialized gene panels.
Invivoscribe said that the facility will serve as an international service laboratory in the Middle East and provide testing for all hematologic diseases, including leukemia and lymphoma.
The partnership will enable the American University of Beirut Medical Center to provide its pharmaceutical and clinical partners in the Middle East with standardized tests and bioinformatics tools provided by Invivoscribe’s Laboratory for Personalized Molecular Medicine clinical facilities in the US, Japan, and Germany.
Financial and other terms of the agreement were not disclosed.
Danaher’s board has approved a quarterly dividend of $.16 per share payable on July 27 to shareholders of record on June 29.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the 360Dx site.